Status:
COMPLETED
Effect of Sitagliptin on Endothelial Progenitor Cells
Lead Sponsor:
University of Padova
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
40-80 years
Phase:
PHASE4
Brief Summary
Endothelial progenitor cells (EPCs) are involved in cardiovascular homeostasis, through angiogenesis and endothelial healing. Diabetic patients have a high risk of cardiovascular events and low levels...
Detailed Description
Diabetic patients suffer an elevated wirk of cardiovascular events, which strongly impact on morbidity and mortality. The mechanisms that lead to cardiovascular disease in diabetes include alterations...
Eligibility Criteria
Inclusion
- Type 2 diabetes;
- Both genders
- Age 40-80
- fasting c-peptide \>=1.0 ng/L
- Therapy with metformin or sulphonylureas
- HbA1c \>7.0%
- No contraindications to sitagliptin use
Exclusion
- Type 1 diabetes
- Age \<40 or \>80
- fasting c-peptide \<1.0 ng/L
- Therapy with TZD
- HbA1c \<=7.0%
- Acute concomitant diseases
- Immunological disorders
- Recent (within 3 months) cardiovascular events or surgery
- Pregnancy and lactation
- Inability to provide informed consent
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00968006
Start Date
October 1 2009
End Date
January 1 2010
Last Update
April 5 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Padova, Medical School
Padua, Italy, 35100